Last reviewed · How we verify
NCT03796026
A Study to Assess the Effect of Seltorexant Compared to Placebo on Respiration During Sleep in Adult Participants With Obstructive Sleep Apnea
Phase 1 trial testing Seltorexant 40 mg in Sleep Apnea, Obstructive in 34 participants. Completed in 14 June 2019.
7 June 2019
Quick facts
| Lead sponsor | Janssen Research & Development, LLC |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 34 |
| Start date | 4 January 2019 |
| Primary completion | 7 June 2019 |
| Estimated completion | 14 June 2019 |
| Sites | 4 locations across United States |
Drugs / interventions tested
- Seltorexant 40 mg — full drug profile →
- Placebo
Conditions studied
- Sleep Apnea, Obstructive — all drugs for Sleep Apnea, Obstructive →
Sponsor
Janssen Research & Development, LLC — full company profile →
Who can join
Adults 18 to 70, any sex, with Sleep Apnea, Obstructive. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the effect of multiple doses of seltorexant compared with placebo on respiration during sleep in adult participants with mild to moderate obstructive sleep apnea.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03796026
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Seltorexant 40 mg
Trials testing the same drug.
- NCT03438461 — A Study to Evaluate the Relative Oral Bioavailability of Seltorexant (JNJ-42847922) After Administration of 3 Different · Phase 1 · completed
Other recruiting trials for Sleep Apnea, Obstructive
Currently open trials in the same condition.
- NCT06828835 — The REPOSE (Reach for Equity in Pediatric Sleep Evaluation) Navigation Intervention · NA · recruiting
- NCT06915831 — Type 1 Diabetes and Obstructive Sleep Apnea · NA · recruiting
- NCT07176767 — The IPAD Cohort Study: Insomnia and Positive Airway Pressure Adherence in Children and Adolescents · recruiting
- NCT06573372 — Evaluating the Diagnostic Efficacy of Smartwatch and Smartphone for Sleep Apnea · recruiting
- NCT06848647 — Treatment of Sleep Apnea to Improve Metabolic Health · recruiting
Other Janssen Research & Development, LLC trials
Trials by the same sponsor.
- NCT07518186 — A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma · Phase 3 · not yet recruiting
- NCT07309445 — A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC · recruiting
- NCT07499232 — A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease · Phase 3 · not yet recruiting
- NCT07438496 — A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus · Phase 3 · recruiting
- NCT07227025 — A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03796026 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Janssen Research & Development, LLC
- Last refreshed: 27 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03796026.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing